New study identifies essential genes for cancer immunotherapy

August 7, 2017, National Cancer Institute
The DNA double helix rests on a field of ACGTs and binary numbers. Credit: Jonathan Bailey, National Human Genome Research Institute

A new study identifies genes that are necessary in cancer cells for immunotherapy to work, addressing the problem of why some tumors don't respond to immunotherapy or respond initially but then stop as tumor cells develop resistance to immunotherapy.

The study, from the National Cancer Institute (NCI), was led by Nicholas Restifo, M.D., a senior investigator with NCI's Center for Cancer Research, with coauthors from NCI; Georgetown University, Washington D.C.; the Broad Institute of MIT and Harvard University, Cambridge, Massachusetts; New York University, New York City; and the University of Pennsylvania, Philadelphia. It was published online in Nature on August 7, 2017. NCI is part of the National Institutes of Health (NIH).

"There is a great deal of interest in , especially for patients who have metastatic ," said Dr. Restifo. "The response to immunotherapy can be fantastic, but understanding why some patients don't respond will help us improve treatments for more patients."

Cancer immunotherapy relies on T cells, a type of cell in the immune system, to destroy tumors. Dr. Restifo and his colleagues have previously shown that the infusion of large numbers of T cells can trigger complete regression of cancer in patients. They and others have also shown that T cells can directly recognize and kill tumor cells.

However, some tumor cells are resistant to the destruction unleashed by T cells. To investigate the basis for this resistance, the researchers sought to identify the in cancer cells that are necessary for them to be killed by T cells.

Working with a melanoma tumor cell line, the researchers used a gene editing technology called CRISPR that "knocks out," or stops the expression, of individual genes in cancer cells. By knocking out every known protein-encoding gene in the and then testing the ability of the gene-modified melanoma cells to respond to T cells, they found more than 100 genes that may play a role in facilitating tumor destruction by T cells.

Once the team identified these "candidate" genes, they sought additional evidence that these genes play a role in susceptibility to T cell-mediated killing. To this end, they examined data on "cytolytic activity," or a genetic profile that shows are responding to T cells, in more than 11,000 patient tumors from The Cancer Genome Atlas, a collaboration between NCI and the National Human Genome Research Institute, also part of NIH. They found that a number of the genes identified in the CRISPR screen as being necessary for tumor cells to respond to T cells were indeed associated with tumor cytolytic activity in patient samples.

One such gene is called APLNR. The product of this gene is a protein called the . Although it had been suspected to contribute to the development of some cancers, this was the first indication of a role in the response to T . Further investigation of tumors from patients resistant to immunotherapies showed that the apelin receptor protein was nonfunctional in some of them, indicating that the loss of this protein may limit the response to immunotherapy treatment.

Shashank Patel, Ph.D., the first author of the study, said the results show that "many more genes than we originally expected play a vital role in dictating the success of cancer immunotherapies."

The researchers wrote that this gene list could serve as a blueprint to study the emergence of resistance to T cell-based cancer therapies. Dr. Restifo noted that if this set of genes is validated in clinical trials, then this data could eventually lead to more effective treatments for patients.

"If we can truly understand mechanisms of resistance to immunotherapy, we might be able to develop new therapeutics," he said. "In fact, in the future, this knowledge could speed the development of a new category of drugs that can circumvent these escape mechanisms of and help patients experience complete responses."

Explore further: Shedding light on cause of resistance to tumor immunotherapy

More information: Shashank J. Patel et al, Identification of essential genes for cancer immunotherapy, Nature (2017). DOI: 10.1038/nature23477

Related Stories

Shedding light on cause of resistance to tumor immunotherapy

July 25, 2017
In tumor immunotherapy, the body's own defense system is activated against the tumor cells. However, for the majority of patients, the tumor cells become resistant to the treatments used. Researchers at the University of ...

A new T-cell population for cancer immunotherapy

May 23, 2017
Scientists at the University of Basel in Switzerland have, for the first time, described a new T cell population that can recognize and kill tumor cells. The open access journal eLife has published the results.

Barrier proteins in tumors are possible key to immunotherapy success

June 28, 2017
By comparing variations in protein expression in tumor samples from a single melanoma patient, researchers from the Johns Hopkins Bloomberg~Kimmel Institute and the Memorial Sloan-Kettering Cancer Center say their findings ...

Patients' immune system may influence effectiveness of cancer immunotherapy

April 2, 2017
Higher or lower levels of certain immune cells in cancer patients may be associated with how well they respond to immunotherapy, according to preliminary results of a study conducted by researchers at the University of Pittsburgh ...

Number of mutations in a tumor varies by age and type of cancer

May 17, 2017
A team of investigators led by researchers at Georgetown Lombardi Comprehensive Cancer Center has found that the tumor mutation load, or TML, in a patient's cancer biopsy varied by age and the type of cancer, along with several ...

Tumor immune fitness determines survival of lung cancer patients

June 19, 2017
In recent years, immunotherapy, a new form of cancer therapy that rouses the immune system to attack tumor cells, has captivated the public's imagination. When it works, the results are breathtaking. But more often than not ...

Recommended for you

Researchers use a molecular Trojan horse to deliver chemotherapeutic drug to cancer cells

February 23, 2018
A research team at the University of California, Riverside has discovered a way for chemotherapy drug paclitaxel to target migrating, or circulating, cancer cells, which are responsible for the development of tumor metastases.

Lab-grown 'mini tumours' could personalise cancer treatment

February 23, 2018
Testing cancer drugs on miniature replicas of a patient's tumour could help doctors tailor treatment, according to new research.

An under-the-radar immune cell shows potential in fight against cancer

February 23, 2018
One of the rarest of immune cells, unknown to scientists a decade ago, might prove to be a potent weapon in stopping cancer from spreading in the body, according to new research from the University of British Columbia.

Study tracks evolutionary transition to destructive cancer

February 23, 2018
Evolution describes how all living forms cope with challenges in their environment, as they struggle to persevere against formidable odds. Mutation and selective pressure—cornerstones of Darwin's theory—are the means ...

Putting black skin cancer to sleep—for good

February 22, 2018
An international research team has succeeded in stopping the growth of malignant melanoma by reactivating a protective mechanism that prevents tumor cells from dividing. The team used chemical agents to block the enzymes ...

Cancer risk associated with key epigenetic changes occurring through normal aging process

February 22, 2018
Some scientists have hypothesized that tumor-promoting changes in cells during cancer development—particularly an epigenetic change involving DNA methylation—arise from rogue cells escaping a natural cell deterioration ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.